KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) Debt to Equity (2020 - 2025)

Historic Debt to Equity for Regeneron Pharmaceuticals (REGN) over the last 6 years, with Q4 2025 value amounting to $0.06.

  • Regeneron Pharmaceuticals' Debt to Equity fell 601.82% to $0.06 in Q4 2025 from the same period last year, while for Dec 2025 it was $0.06, marking a year-over-year decrease of 601.82%. This contributed to the annual value of $0.06 for FY2025, which is 601.82% down from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Debt to Equity stood at $0.06 for Q4 2025, which was down 601.82% from $0.06 recorded in Q3 2025.
  • Regeneron Pharmaceuticals' 5-year Debt to Equity high stood at $0.17 for Q1 2021, and its period low was $0.06 during Q4 2025.
  • Its 5-year average for Debt to Equity is $0.09, with a median of $0.08 in 2023.
  • Its Debt to Equity has fluctuated over the past 5 years, first tumbled by 4129.01% in 2021, then tumbled by 517.59% in 2025.
  • Regeneron Pharmaceuticals' Debt to Equity (Quarter) stood at $0.11 in 2021, then fell by 17.13% to $0.09 in 2022, then fell by 12.67% to $0.08 in 2023, then fell by 11.45% to $0.07 in 2024, then dropped by 6.02% to $0.06 in 2025.
  • Its Debt to Equity stands at $0.06 for Q4 2025, versus $0.06 for Q3 2025 and $0.07 for Q2 2025.